Market Overview

Unity Biotech Is A Buy On 'Novel Biology,' Morgan Stanley Says In Positive Initiation

Share:
Unity Biotech Is A Buy On 'Novel Biology,' Morgan Stanley Says In Positive Initiation
Related
The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO
Benzinga's Week Ahead: Can Facebook, Apple Earnings Rescue The Stock Market?

Unity Biotechnology Inc (NASDAQ: UBX) has fallen 22 percent since its May 3 initial public offering. Nonetheless, three sell-side firms initiated price targets implying significant upside Tuesday.

The Rating

Morgan Stanley analysts Matthew Harrison and David Lebowitz initiated coverage on Unity with an Overweight rating and $25 price target.

The Thesis

The analysts are inspired by “novel biology” and compelling preclinical data.

Unity hypothesizes that it can heal chronic illness such as osteoarthritis and eye disease by eliminating non-dividing cells that otherwise drive inflammation through protein build-ups. It recently released preclinical data demonstrating a 35-percent increase in mice longevity with no sign of arthritis and fewer instances of cataracts.

“While [the] initial focus of knee arthritis is narrow, we believe proof-of-concept could lead to platform validation,” the analysts said in a note. 

Clinical data on osteoarthritis is expected as soon as the first quarter of 2019 and could catalyze stock movement, according to Morgan Stanley. 

Unity Biotechnology also intends to file Investigational New Drug applications next year to expand the platform.

Price Action

Unity shares were up 0.15 percent at $13.02 at the close Tuesday.

Related Links:

T2Biosystems Announces FDA Approval For Sepsis Test: 'This Is A Game-Changer'

Transenterix Pops On FDA Clearance For Senhance Indication Expansion

Latest Ratings for UBX

DateFirmActionFromTo
Dec 2018Morgan StanleyMaintainsOverweightOverweight
Sep 2018MizuhoInitiates Coverage OnBuy
May 2018CitigroupInitiates Coverage OnBuy

View More Analyst Ratings for UBX
View the Latest Analyst Ratings

Posted-In: David Lebowitz Matthew HarrisonAnalyst Color Biotech Price Target Initiation Analyst Ratings General Best of Benzinga

 

Related Articles (UBX)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
MDRXKeyBancUpgrades0.0
ANETNomuraUpgrades260.0
CNPRBC CapitalUpgrades34.0
FISVOppenheimerUpgrades88.0
FNDUBSUpgrades37.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Today In Cryptocurrency: EOS ICO Raises $4 Billion, Wikipedia Founder Calls Cryptos 'Absolutely, Definitely' A Bubble

PermRock's Stock A 'Straightforward Opportunity,' Stifel Says